- Home
- Publications
- Publication Search
- Publication Details
Title
Novel immunomodulatory compounds in multiple myeloma
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 22, Issue 2, Pages 207-215
Publisher
Informa Healthcare
Online
2012-12-25
DOI
10.1517/13543784.2013.749235
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
- (2012) S. Kumar et al. BLOOD
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- Novel therapies in MM: from the aspect of preclinical studies
- (2011) Teru Hideshima et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
- (2011) F Cavallo et al. LEUKEMIA
- Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies
- (2011) S Sinha et al. LEUKEMIA
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide
- (2010) I N M Micallef et al. BONE MARROW TRANSPLANTATION
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
- (2010) M Q Lacy et al. LEUKEMIA
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
- (2009) D. Reece et al. BLOOD
- Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
- (2009) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- First thalidomide clinical trial in multiple myeloma: a decade
- (2008) F. van Rhee et al. BLOOD
- Thalidomide for treatment of multiple myeloma: 10 years later
- (2008) A. Palumbo et al. BLOOD
- Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation
- (2008) Matthew J. Streetly et al. BRITISH JOURNAL OF HAEMATOLOGY
- A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
- (2008) Marie von Lilienfeld-Toal et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma
- (2008) H Paripati et al. LEUKEMIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More